Wellington Management Group’s Aclaris Therapeutics ACRS Stock Holding History

Wellington Management Group’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$964K	Sell	257,156 -7,203	-3%	-$24.3K	﹤0.01%	1683
2025 Q4	$796K	Buy	+264,359	New	+$668K	﹤0.01%	1757
2023 Q4	–	Sell	-6,979,844	Closed	-$47.8M	–	1816
2023 Q3	$47.8M	Sell	6,979,844 -658,024	-9%	-$5.62M	0.01%	703
2023 Q2	$79.2M	Buy	7,637,868 +265,267	+4%	+$2.4M	0.02%	601
2023 Q1	$59.6M	Buy	7,372,601 +1,888,588	+34%	+$24M	0.01%	650
2022 Q4	$86.4M	Buy	5,484,013 +2,030,160	+59%	+$32.7M	0.02%	557
2022 Q3	$54.4M	Sell	3,453,853 -1,447,410	-30%	-$22.8M	0.01%	651
2022 Q2	$68.4M	Sell	4,901,263 -828,990	-14%	-$11.6M	0.01%	611
2022 Q1	$98.8M	Buy	5,730,253 +190,985	+3%	+$2.61M	0.02%	584
2021 Q4	$80.5M	Buy	5,539,268 +118,815	+2%	+$1.8M	0.01%	688
2021 Q3	$97.6M	Buy	5,420,453 +722,704	+15%	+$11.6M	0.02%	633
2021 Q2	$82.5M	Buy	4,697,749 +3,866,420	+465%	+$87.8M	0.01%	686
2021 Q1	$20.9M	Buy	+831,329	New	+$16.3M	﹤0.01%	1060
2018 Q2	–	Sell	-32,894	Closed	-$577K	–	2218
2018 Q1	$577K	Buy	+32,894	New	+$697K	﹤0.01%	1994

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group's ACRS Position: Q1 2026 in Review

Wellington Management Group reduced its Aclaris Therapeutics (ACRS) stake by 2.7% in Q1 2026, selling an estimated $24.3K and leaving 257,156 shares worth $964K. The position accounts for ﹤0.01% of the portfolio, ranked #1683.

Wellington Management Group first reported a position in ACRS in Q1 2018 and has held it in 14 quarters since. The position peaked at $98.8M in Q1 2022. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

Wellington Management Group held 257,156 shares of Aclaris Therapeutics worth $964K as of Q1 2026.
Wellington Management Group sold 7,203 Aclaris Therapeutics shares in Q1 2026, an estimated $24.3K.
Aclaris Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q1 2026, its #1683 holding.
Wellington Management Group first reported a position in Aclaris Therapeutics in Q1 2018 and has held it in 14 quarters since.
Wellington Management Group's Aclaris Therapeutics position peaked at $98.8M in Q1 2022.
136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.